Nasdaq · Healthcare
SINOVAC BIOTECH LTD (SVA)
As-reported financials and recent SEC filings for SINOVAC BIOTECH LTD, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$386.0M
Net income
$-198.8M
Net margin
-51.5%
Diluted EPS
$-0.83
ROE
-3.1%
P/E (TTM)
6.7×
Market cap
—
Debt / equity
0.1×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $386.0M | $361.4M | $470.2M | $1.47B | $19.37B |
| Gross profit | $262.0M | $220.7M | $323.3M | $815.2M | — |
| Operating income | $-490.1M | $-505.5M | $-714.0M | $-509.0M | $17.62B |
| Net income | $-198.8M | $40.7M | $-120.9M | $-60.0M | $14.12B |
| Diluted EPS | $-0.83 | $1.27 | $-0.19 | $0.20 | $113.44 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
6-K2026-06-15
View on EDGAR →6-K2026-06-05
View on EDGAR →20-F2026-06-05
View on EDGAR →6-K2026-05-29
View on EDGAR →6-K2026-05-21
View on EDGAR →6-K2026-05-08
View on EDGAR →6-K2026-05-07
View on EDGAR →NT 20-F2026-04-30
View on EDGAR →Go deeper on SVA
Search SINOVAC BIOTECH LTD’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.